A high rate of incorrect biopsies has tangled the mid-stage results for Nymox Pharmaceutical’s experimental prostate cancer drug. Investigators say that NX-1207 reduced the rate of disease progression in patients, but they couldn’t determine if the drug hits its primary endpoint due to “the high percentage of false negative repeat biopsies in the active surveillance control.” …read more

Source: Biopsy snafu torpedoes PhII prostate cancer data for Nymox


0 No comments